Aflibercept and Bevacizumab for Diabetic Maculopathies
Status:
RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to to evaluate the clinical outcomes following treatment with bevacizumab versus aflibercept. These outcomes include:
* Functional changes: The visual outcomes achieved by testing visual acuity
* Anatomical changes: macular thickness and edema by optical coherence tomography (OCT).